Conatus Pharmaceuticals Inc., a San Diego, CA-based biopharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology, has received an additional $7.5m investment by MPM Capital, closing its Series B round at $32.5m.
The first closing was held in early February, 2011 (see news).
In conjunction with the investment, Jim Scopa from MPM will join Conatus’ Board of Directors.
The company will use the proceeds to advance the clinical development of CTS-1027, a novel clinical-stage drug candidate it licensed from F. Hoffman-La Roche, Ltd. and the subject of multiple Phase 2 clinical trials in hepatitis C (HCV)-infected patients.
FinSMEs
12/04/2011